Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.

abstract：:Thrombotic microangiopathy (TMA) after hematopoietic stem-cell transplantation (HSCT) or solid-organ transplantation is a serious complication that may be associated with diverse clinical conditions. The reported incidence varies widely, in part due to different diagnostic criteria. Currently, the diagnosis is based m...

journal_title：Seminars in thrombosis and hemostasis

authors： Qu L,Kiss JE

更新日期：2005-12-01 00:00:00

abstract：:The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecu...

journal_title：Seminars in thrombosis and hemostasis

authors： Alban S

更新日期：2001-10-01 00:00:00

abstract：:Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. B...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,de Peuter OR,Kamphuisen PW

更新日期：2009-09-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:Currently, in Germany, there is a successful program where patients monitor their own coagulation status through self-testing. The advent of a new generation of coagulometers has allowed more and more patients to use self-testing to monitor their coagulation status. The development of a structured training program by ...

journal_title：Seminars in thrombosis and hemostasis

authors： Taborski U,Müller-Berghaus G

更新日期：1999-01-01 00:00:00

abstract：:Disseminated intravascular coagulation (DIC) is a syndrome characterized by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the circulation. There is ample experimental and pathological evidence that the fibrin deposition contributes to multiple organ failure. The massive...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,de Jonge E,van der Poll T,ten Cate H

更新日期：2001-12-01 00:00:00

abstract：:Self-control and self-management of oral anticoagulant therapy have become more and more attractive for patients undergoing long-term treatment. In our training center, we examined 50 patients who took part in a standardized training course for self-management. Patients (36 men, 14 women) were preselected according to...

journal_title：Seminars in thrombosis and hemostasis

authors： Mörsdorf S,Erdlenbruch W,Taborski U,Schenk JF,Erdlenbruch K,Novotny-Reichert G,Krischek B,Wenzel E

更新日期：1999-01-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:Immune thrombocytopenic purpura (ITP) is a bleeding disorder and is traditionally divided in acute and chronic forms based on the duration of the disease. Chronic ITP is characterized by a persistence of thrombocytopenia for more than 6 months. Ten to 20% of children with ITP and almost all adults will develop the chr...

journal_title：Seminars in thrombosis and hemostasis

authors： Kühne T,Imbach P

更新日期：1998-01-01 00:00:00

abstract：: ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2019-02-01 00:00:00

abstract：:Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen manageme...

journal_title：Seminars in thrombosis and hemostasis

authors： McGlasson DL,Fritsma GA

更新日期：2009-03-01 00:00:00

abstract：:The liver is the main site of synthesis and/or clearance of proteins involved in fibrinolysis. Therefore, chronic liver disease, including cirrhosis, leads to altered plasma levels of fibrinolytic proteins. Historical studies using in vitro clot lysis assays suggested that patients with chronic liver disease had accel...

journal_title：Seminars in thrombosis and hemostasis

authors： Leebeek FW,Rijken DC

更新日期：2015-07-01 00:00:00

abstract：:Thrombotic events are uncommon disorders in childhood but increasingly recognized due to the progress made in the understanding of the hemostasis system and the importance of thromboembolic disorders in children. Multiple clinical underlying conditions and prothrombotic disorders contribute to the development of throm...

journal_title：Seminars in thrombosis and hemostasis

authors： Tormene D,Gavasso S,Rossetto V,Simioni P

更新日期：2006-10-01 00:00:00

abstract：:Patients undergoing surgery for malignancy are at increased risk of initial and recurrent venous thromboembolism (VTE). Several factors have been found to increase the risk of deep vein thrombosis (DVT) in cancer patients both during the first days after the operation and after discharge from hospital. Although, in ge...

journal_title：Seminars in thrombosis and hemostasis

authors： Khushal A,Quinlan D,Alikhan R,Gardner J,Bailey C,Cohen A

更新日期：2002-12-01 00:00:00

abstract：:Physiologic regulation of fibrinolysis plays an important role in the control of hypercoagulable states and thrombogenesis. Both the hereditary and acquired conditions leading to fibrinolytic deficit result in thrombotic complications leading to arterial and venous occlusive disorders. Several changes in physiologic s...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Hoppensteadt DA,Jeske WP,Ahmad S,Bick RL

更新日期：1999-01-01 00:00:00

abstract：:Hemophilia A and B gene therapy requires long-term and stable expression of coagulation factor VIII (FVIII) or factor IX (FIX), respectively, and would need to compare favorably with protein replacement therapy. Onco-retroviral and lentiviral vectors are attractive vectors for gene therapy of hemophilia. These vectors...

journal_title：Seminars in thrombosis and hemostasis

authors： Van Damme A,Chuah MK,Collen D,VandenDriessche T

更新日期：2004-04-01 00:00:00

abstract：:Despite long-standing knowledge about the relationship between thrombosis and atherosclerosis, the specific role of thrombin in modulating atherosclerosis and the response to vascular injury is not well understood. Thrombin receptor stimulation in vitro signals many cellular events that are associated with the respons...

journal_title：Seminars in thrombosis and hemostasis

authors： McNamara CA,Sarembock IJ,Bachhuber BG,Stouffer GA,Ragosta M,Barry W,Gimple LW,Powers ER,Owens GK

更新日期：1996-01-01 00:00:00

abstract：:Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well...

journal_title：Seminars in thrombosis and hemostasis

authors： Sierko E,Wojtukiewicz MZ

更新日期：2007-10-01 00:00:00

abstract：:Thrombophilia includes multiple inherited and acquired risk factors that determine a shift in the balance of procoagulant and anticoagulant factors promoting hypercoagulability, which is associated with an increased risk of venous thromboembolism (VTE). VTE is characterized by more common clinical manifestations, such...

journal_title：Seminars in thrombosis and hemostasis

authors： Lussana F,Dentali F,Ageno W,Kamphuisen PW

更新日期：2007-09-01 00:00:00

abstract：:Life expectancy for persons with hemophilia (PWH) has considerably increased in the last decades as a direct result of the availability of modern therapies to control the clotting defect. Because their life expectancy now matches that of the general population, PWH are experiencing age-related comorbidities, such as, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Santoro C,Franchini M,Mannucci C,Mogavero S,Molinari AC,Schinco P,Tagliaferri A,Santoro RC

更新日期：2013-10-01 00:00:00

abstract：:Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Tagliaferri A,Franchini M

更新日期：2010-02-01 00:00:00

abstract：:Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

更新日期：1983-10-01 00:00:00

abstract：:Heparin preparations have been used for prophylaxis and treatment of deep vein thrombosis for many years. Several biologic effects of heparin are known. Since 1978, there have been several reports about reversible elevation in serum values of AST and ALT in patients and healthy volunteers given heparin in small and hi...

journal_title：Seminars in thrombosis and hemostasis

authors： Christiansen HM,Lassen MR,Borris LC,Sørensen JV,Rahr HB,Jørgensen LN,Jørgensen PW,Hauch O

更新日期：1991-10-01 00:00:00

abstract：:Protamine sulfate has been used for many years to reverse the effects of unfractionated heparin, but it can cause hemodynamic changes and other serious side effects. Platelet factor 4 (PF4) is a naturally occurring protein synthesized in megakaryocytes and eventually stored in the alpha granules of platelets for later...

journal_title：Seminars in thrombosis and hemostasis

authors： Mixon TA,Dehmer GJ

更新日期：2004-06-01 00:00:00

abstract：:Despite numerous past and ongoing efforts, there remains significant variation in results from assays for the major antiphospholipid antibodies (aPL), namely anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI), and lupus anticoagulant (LA). There is therefore a need to produce comprehensive guidelines on ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wong RC,Favaloro EJ

更新日期：2008-06-01 00:00:00

abstract：:Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regu...

journal_title：Seminars in thrombosis and hemostasis

authors： Kavanagh D,Goodship TH

更新日期：2006-03-01 00:00:00

abstract：:The delicate biochemistry of coagulation and anticoagulation is greatly affected by deviations from the optimal temperature required for the interactions between various coagulation enzymes, cellular receptors, and intracellular mechanisms. Hyperthermia will lead to a prothrombotic state and, if sufficiently severe su...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2018-10-01 00:00:00

abstract：:The number of hip fractures in anticoagulated patients is predicted to increase, due to people living longer. However, evidence regarding urgent perioperative management of elderly patients with hip fracture who take oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) is scarce. In this article, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Grandone E,Ostuni A,Tiscia GL,Marongiu F,Barcellona D

更新日期：2019-03-01 00:00:00

abstract：:These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

journal_title：Seminars in thrombosis and hemostasis

authors： Hiebert L,Liu JM

更新日期：1991-01-01 00:00:00